Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…

Cellectar Biosciences today announced the effective prices of $4.00 per share of common stock of an underwritten public offering to raise approximately $16.56 million. According to a release, this includes the full…

The Madison community is important to the success of Exact Sciences, CEO Kevin Conroy said at the annual shareholder meeting held today at the Edgewater Hotel. “If you have a…

Cellectar Biosciences announced today a patient, enrolled in the CLR 131 Phase 2 trial, showed a 94 percent reduction in tumor burden and complete resolution in four of five targeted…

Gregor Diagnostics, a molecular diagnostics company developing an at-home screening test for prostate cancer, closed a $900,000 round of seed financing, the company announced recently. According to a release, the…

Zurex Pharma, a pharma and medical technology company with a novel antimicrobial technology platform, raised $9 million in advance of a pending new drug application (NDA) submission, the company announced…

Along with the $20 million funding round announced last week, Propeller Health announced recently that McKesson Ventures also has made an investment in the company. According to a release, the undisclosed…

FUJIFILM Cellular Dynamics, Inc. (FCDI) and the University of California – Irvine have entered into an exclusive patent license agreement that will enable FCDI to differentiate pluripotent stem cells into…

Exact Sciences, along with researchers at the Mayo Clinic, announced today that they have developed a blood test that correctly identified 95 percent of the cases of a common form…

Propeller Health announced today that it has raised $20 million to support its investment in its pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease….